Second infliximab biosimilar on its way


The PBAC has recommended the listing of a second biosimilar to infliximab (Remicade). A year after Pfizer’s biosimilar (Inflectra) gained PBS listing MSD’s biosimilar Renflexis is now recommended by the PBAC on a cost minimisation basis with infliximab (Remicade) for all indications – rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, chronic plaque psoriasis, Crohn’s disease, fistulating ...


Already a member? Login to keep reading


OR
© 2017 the limbic